Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
84.06
+1.02 (+1.23%)
Streaming Delayed Price
Updated: 2:14 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
34
35
Next >
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
April 28, 2023
GILD earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger
April 27, 2023
The company sells Trodelvy and two cell therapies. Sales of all three surged.
Via
Investor's Business Daily
P/E Ratio Insights for Gilead Sciences
April 27, 2023
Via
Benzinga
What Does Gilead Sciences' Debt Look Like?
April 27, 2023
Via
Benzinga
Better Buy: Pfizer vs. Gilead
April 27, 2023
Pfizer and Gilead look cheap right now.
Via
The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
April 26, 2023
Via
Benzinga
Expert Ratings for Gilead Sciences
April 12, 2023
Via
Benzinga
Could Gilead Sciences Stock Help You Become a Millionaire?
April 12, 2023
The company's dominant HIV therapies and growing oncology pipeline are delivering.
Via
The Motley Fool
P/E Ratio Insights for Gilead Sciences
April 11, 2023
Via
Benzinga
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
April 25, 2023
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch.
Via
InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
2 Excellent Dividend Stocks to Buy for Less Than $100
April 25, 2023
Both companies are steals at current levels.
Via
The Motley Fool
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'
April 21, 2023
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc.
Via
Benzinga
Strong Quant Screens Say These 7 Growth Stocks Are a Buy
April 19, 2023
StockRover’s quant screen is a grading system that brings up rewarding growth stocks to buy for income investors.
Via
InvestorPlace
A Look Into Gilead Sciences' Debt
April 11, 2023
Via
Benzinga
6 Reasons to Buy Gilead Sciences Stock
April 06, 2023
The healthcare stock could be a solid pillar to build your portfolio around.
Via
The Motley Fool
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
April 15, 2023
Long-term investors looking for income should especially like these stocks.
Via
The Motley Fool
Dividend Income Update March 2023
April 12, 2023
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio.
Via
Talk Markets
If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today
April 10, 2023
Would you have been better off investing in the S&P 500?
Via
The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
April 10, 2023
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.
Via
Benzinga
3 Dividend Stocks Billionaires Seem to Love
April 09, 2023
It sometimes pays to follow the lead of successful people.
Via
The Motley Fool
Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough
April 06, 2023
Via
Benzinga
GILD - Chart Of The Week
April 05, 2023
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December.
Via
Talk Markets
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
March 31, 2023
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...
Via
Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
March 31, 2023
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many...
Via
Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
March 31, 2023
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the...
Via
Benzinga
Is It Time to Buy These Ultra-Cheap Dividend Stocks?
March 29, 2023
These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.